Actinium Pharmaceuticals (ATNM) Non Operating Income (2010 - 2026)
Actinium Pharmaceuticals (ATNM) posted quarterly Non Operating Income of $381000.0 for Q1 2026, down 45.57% year-over-year from $700000.0 in Q1 2025, and down 19.62% quarter-over-quarter from $474000.0 in Q4 2025.
Actinium Pharmaceuticals (ATNM) Non Operating Income (2010 - 2026) Analysis & Trends
Actinium Pharmaceuticals (ATNM) has reported Non Operating Income for 17 consecutive years, with $381000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Non Operating Income fell 45.57% year-over-year to $381000.0; the TTM figure through Mar 2026 stood at $2.0 million (down 44.1% YoY), while the FY2025 annual figure was $2.4 million, down 39.14% from the prior year.
- Non Operating Income declined to $381000.0 in Q1 2026 per ATNM's latest filing, from $474000.0 in the prior quarter.
- Across five years, Non Operating Income topped out at $1.1 million in Q3 2023 and bottomed at $35000.0 in Q1 2022.
- Historically, Non Operating Income has averaged $635764.7 across 5 years, with a median of $625000.0 in 2025.
- Annual changes were most pronounced in 2022 — Non Operating Income surged 1594.74% — and 2025, when it sank 45.69%.
- Actinium Pharmaceuticals' Non Operating Income stood at $644000.0 in 2022, then jumped by 58.23% to $1.0 million in 2023, then retreated by 16.29% to $853000.0 in 2024, then sank by 44.43% to $474000.0 in 2025, then slipped by 19.62% to $381000.0 in 2026.
- Business Quant data shows ATNM's Non Operating Income at $381000.0 in Q1 2026, $474000.0 in Q4 2025, and $561000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Op. Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 234.30 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | -53.64 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -51.63 Mn |
| 10 | Actinium Pharmaceuticals | 35.01 Mn | 35.01 Mn | - | 336,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 336,000.00 |
| Mar 31, 2026 | 381,000.00 |
| Dec 31, 2025 | 474,000.00 |
| Sep 30, 2025 | 561,000.00 |
| Jun 30, 2025 | 625,000.00 |
| Mar 31, 2025 | 700,000.00 |
| Dec 31, 2024 | 853,000.00 |
| Sep 30, 2024 | 1.03 Mn |
| Jun 30, 2024 | 1.07 Mn |
| Mar 31, 2024 | 927,000.00 |
| Dec 31, 2023 | 1.02 Mn |
| Sep 30, 2023 | 1.08 Mn |
| Jun 30, 2023 | 461,000.00 |
| Mar 31, 2023 | 547,000.00 |
| Dec 31, 2022 | 644,000.00 |
| Sep 30, 2022 | 325,000.00 |
| Jun 30, 2022 | 83,000.00 |
| Mar 31, 2022 | 35,000.00 |
| Dec 31, 2021 | 38,000.00 |
| Sep 30, 2021 | 46,000.00 |